Business
BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What’s New Award in the Health Category
JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and
About this update from Scynexis, Inc.
[{"type":"text","content":"JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that BREXAFEMME® (ibrexafungerp tablets) has been named as a Popular Science 2021 “Best of What’s New” award winner in the Health category. “2021 has been an action-packed year of innovation in health care, and we are honored that BREXAFEMME has been recognized alongside major disruptive innovations like the COVID-19 vaccines, a new treatment for Ebola, and other therapies and devices that are improving global health,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “BREXAFEMME represents the first new antifungal class approved by the U.S. Food and Drug Administration in more than 20 years and the first new treatment approved for vaginal yeast infections in more than 25 years. It is a novel one-day oral treatment option for the millions of women who suffer from yeast infections and works by killing the fungi causing the infection. We are thrilled to have this groundbreaking product recognized for its innovation.” Every year since 1988, the editors of Popular Science have reviewed thousands of products in search of the top 100 innovations—breakthrough products and technologies that represent significant advancements in their categories. Best of What’s New awards are presented to products and technologies in 10 categories: Aerospace, Automotive, Engineering, Entertainment, Gadgets, Health, Home, Personal Care, Sports & Outdoors, and Security. About BREXAFEMME® (ibrexafungerp tablets) BREXAFEMME is a novel oral antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. Its mechanism of action, glucan synthase inhibition, is fungicidal against Candida species, meaning it kills fungal cells.1 The New Drug Application (NDA) for BREXAFEMME was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. The NDA was supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated efficacy and a favorable tolerability profile in women with VVC. BREXAFEMME represents the first approved drug in a new a...